IRF7 and astrocytoma (excluding glioblastoma): The IRF7 high‐expression group included WHO grade II, WHO grade III, WHO grade IV, 1p19q non‐codeleted, IDH wild‐type, progressive disease and stable disease, astrocytoma, oligoastrocytoma, oligodendroglioma, and glioblastoma tumors and had a worse prognosis (p < 0.05) (Figure S3A‒O).